...
首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Meta-Analysis of the Clinical Value of Danshen Injection and Huangqi Injection in Liver Cirrhosis
【24h】

Meta-Analysis of the Clinical Value of Danshen Injection and Huangqi Injection in Liver Cirrhosis

机译:丹参,黄芪注射液治疗肝硬化临床价值的Meta分析

获取原文
获取原文并翻译 | 示例
           

摘要

Objective. To evaluate the clinical value of Danshen injection and Huangqi injection for the treatment of liver cirrhosis. Methods. The Chinese Biomedical Literature Database (CBM), Chinese Scientific Journals Full-Text Database (VIP), Wanfang Database, China National Knowledge Infrastructure (CNKI), PubMed, and EMBASE database were searched to collect the literatures about the randomized controlled trials involving the treatment of liver cirrhosis with Danshen injection combined with Huangqi injection, and the data analyses were performed using RevMan 4.2 software. Results. A total of 11 studies involving 1086 patients (trials group: 554 cases, control group: 532 cases) were included in this study. Compared with those in control group, the meta-analysis showed-that the total effectiveness rate and the level of serum albumin increased, while serum total bilirubin, alanine transmninase, type III procollagen, hyaluronic acid, laminin, and type-IV collagen decreased in trials group. The Jadad score ranged from 1 to 2 and the funnel plot analysis suggests that publication bias may occur. Conclusions. Danshen injection combined with Huangqi injection may promote the curative efficacy of liver cirrhosis, which is a promising novel treatment approach. The exact outcome needs to perform rigorously designed, multicenter, and large randomized controlled trials.
机译:目的。评价丹参注射液和黄芪注射液治疗肝硬化的临床价值。方法。搜索中国生物医学文献数据库(CBM),中国科学期刊全文数据库(VIP),万方数据库,中国国家知识基础设施(CNKI),PubMed和EMBASE数据库,以收集有关涉及该治疗的随机对照试验的文献丹参注射液配合黄芪注射液治疗肝硬化的临床资料,采用RevMan 4.2软件进行数据分析。结果。本研究共包括11项研究,涉及1086例患者(试验组:554例,对照组:532例)。荟萃分析显示,与对照组相比,总有效率和血清白蛋白水平升高,而血清总胆红素,丙氨酸转氨酶,Ⅲ型胶原,透明质酸,层粘连蛋白和Ⅳ型胶原却降低了。试验组。 Jadad得分介于1到2之间,并且漏斗图分析表明可能会出现发布偏倚。结论丹参注射液联合黄芪注射液可促进肝硬化的疗效,是一种很有前途的新治疗方法。确切的结果需要执行严格设计的多中心大型随机对照试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号